Lupin Manufacturing Solutions Expands Dabhasa Facility to Boost CRDMO Capabilities

Lupin Manufacturing Solutions, a subsidiary of global pharmaceutical company Lupin Limited, has announced the expansion of its manufacturing facility in Dabhasa. 

The move marks an important step in strengthening the company’s contract research, development and manufacturing organisation capabilities while enhancing its peptide building-blocks platform.

Expansion of Manufacturing Infrastructure

The expansion includes the addition of a new block within the Dabhasa facility designed to support the company’s growing CRDMO operations. The upgraded infrastructure is expected to improve the facility’s ability to handle complex pharmaceutical development and manufacturing processes.

Along with the new block, the company has also added two specialised units dedicated to peptide manufacturing. These units will increase production capacity and enable more flexible manufacturing operations.

Focus on Peptide-Based Therapeutics

Peptides and biologic antibody drug conjugates are becoming increasingly important in modern drug development. These therapies often involve complex molecular structures that require advanced manufacturing technologies and specialised facilities.

The expanded infrastructure will allow Lupin Manufacturing Solutions to strengthen its ability to produce peptide building blocks, including protected amino acids, which are critical components used in developing advanced therapeutics.

Supporting Global Pharmaceutical Demand

The expansion also aims to help the company meet the rising global demand for high-quality pharmaceutical ingredients and complex drug formulations. With enhanced development capabilities and flexible production systems, the facility will support both research and commercial-scale manufacturing.

Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide.”

Lupin Share Price Today

On March 19, 2026, Lupin share price (NSE: LUPIN) opened at ₹2,278.00, touching the day’s low at ₹2,264.90, as of 11:52 AM on the NSE.

Also Read: Alkem Laboratories - German Health Authority Issues EU GMP Certificate for Baddi Plant!

Conclusion

The expansion of the Dabhasa facility reflects Lupin Manufacturing Solutions’ commitment to strengthening its global CRDMO capabilities. By investing in advanced peptide manufacturing infrastructure, the company aims to support the growing demand for complex therapies and contribute to innovation in the pharmaceutical industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.